IRCT201210231584N3已完成2 期
Imatinib Treatment for Secondary Progressive Multiple Sclerosis: A Randomized Control Trial Study Assessing Clinical and Radiological Responses and adverse effects in comparison with Novanterone
Vice chancellor for research, Tehran University of Medical Sciences0 个研究点目标入组 28 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 40 years（—）
- 性别
- All
入选标准
- •SPMS patients with relapse; EDSS between 3 and 5; age between 18 and 40
- •Exclusion criteria: History of other autoimmune disorder or chronic hematologic, renal, liver or infectious diseases; Pregnancy; lactation; History of HIV and Hepatitis; History of cancer especially breast tumor; History of recent herpes zoster infection; History of cytotoxic drugs consumption during recent three months; History of high dose corticosteroid during recent two months.
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Imatinib therapy for agressive colon cancers.colon cancerEUCTR2014-003965-11-NLniversity Medical Center Utrecht
已完成
2 期
Targeted therapy with imatinib for treatment of poor prognosis mesenchymal-type resectable colon cancer: a proof-of-concept study in the preoperative window period.colon cancerNL-OMON47074Oncologie27
已完成
2 期
Effect of Imatinib Mesylate in patients undergone allogeneic bone marrow transplantation who show chronic coetaneous involvement Graft Versus-Host Disease.cutaneous cGVHD.Graft-versus-host reaction or diseaseIRCT201302261030N12Hematology-Oncology and SCT Research Center28
Enrolling By Invitation
不适用
Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT TrialChronic Myeloid Leukemia (CML)NCT06646978Poitiers University Hospital787
招募中
2 期
Phase II trial using imatinib combined with chemotherapy for newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)ewly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)JPRN-UMIN000001226Japan Adult Leukemia Study Group66